◀ Back to TP53

SP1 — TP53

Pathways - manually collected, often from reviews:

• OpenBEL Selventa BEL large corpus: SP1 → TP53 (decreases, TP53 Activity)
  Evidence: direct interaction of the p53 protein with the transcription factor Sp1 prevents transcriptional activation of the VEGF promoter in breast cancer cells and inhibits the hypoxic induction of Src kinase in studies with colon and endometrial cancinoma, stable transfection of wild-type p53 resulted in decreased VEGF expression
• BioCarta overview of telomerase protein component gene htert transcriptional regulation: p53/SP1 complex (TP53-SP1) → SP1 (modification, collaborate)
• BioCarta overview of telomerase protein component gene htert transcriptional regulation: p53/SP1 complex (TP53-SP1) → p53 (TP53) (modification, collaborate)
• BioCarta overview of telomerase protein component gene htert transcriptional regulation: SP1 → p53 (TP53) (modification, collaborate)
• FastForward regulation: SP1 → TP53 (transcriptional regulation, unknown)
  Evidence: DNABINDING
• FastForward regulation: SP1 → TP53 (transcriptional regulation, unknown) Qin et al., Mol Endocrinol 2002*
  Evidence: DNABINDING
• NCI Pathway Database Direct p53 effectors: p53 (tetramer)/SP1 complex (TP53-SP1) → SP1 (SP1) (modification, collaborate) Innocente et al., FEBS Lett 2005*
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Direct p53 effectors: p53 (tetramer)/SP1 complex (TP53-SP1) → p53 (tetramer) complex (TP53) (modification, collaborate)
  Innocente et al., FEBS Lett 2005*
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Direct p53 effectors: SP1 (SP1) → p53 (tetramer) complex (TP53) (modification, collaborate)
  Innocente et al., FEBS Lett 2005*
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Direct p53 effectors: p53 (tetramer)/SP1 complex (TP53-SP1) → Cyclin B1 (CCNB1) (transcription, inhibits) Innocente et al., FEBS Lett 2005*
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: p53 (tetramer)/SP1 complex (TP53-SP1) → SP1 (SP1) (transcription, inhibits) Innocente et al., FEBS Lett 2005*
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: SP1 (SP1) → p53 (tetramer) complex (TP53) (transcription, activates)
  Bist et al., Biochemistry 2000
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: SP1 (SP1) → p53 (tetramer) complex (TP53) (transcription, activates)
  Nakano et al., Mol Cell 2001, Koutsodontis et al., Biochem J 2005, Shi et al., Mol Cell 2007, Das et al., Cell 2007, Gamper et al., Mol Cell Biol 2008, Jansson et al., Nat Cell Biol 2008
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: SP1 (SP1) → p53 (tetramer) complex (TP53) (transcription, activates)
  Shikama et al., Mol Cell 1999, Thornborrow et al., J Biol Chem 2001, Thornborrow et al., Oncogene 2002, Hudson et al., J Biol Chem 2005, Sykes et al., Mol Cell 2006
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: SP1 (SP1) → p53 (tetramer) complex (TP53) (transcription, activates)
  Nakano et al., Mol Cell 2001, Koutsodontis et al., Biochem J 2005, Wu et al., Cell 2005, Tang et al., Mol Cell 2006, Sykes et al., Mol Cell 2006, Shi et al., Mol Cell 2007, Gamper et al., Mol Cell Biol 2008
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: SP1 (SP1) → p53 (tetramer) complex (TP53) (transcription, activates)
  Jaiswal et al., J Biol Chem 2001*
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: SP1 (SP1) → p53 (tetramer) complex (TP53) (transcription, activates)
  Thornborrow et al., J Biol Chem 2001, Thornborrow et al., Oncogene 2002, Hudson et al., J Biol Chem 2005, Budhram-Mahadeo et al., Nucleic Acids Res 2006*, Sykes et al., Mol Cell 2006
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: SP1 (SP1) → p53 (tetramer) complex (TP53) (transcription, activates)
  Thornborrow et al., J Biol Chem 2001, Samuels-Lev et al., Mol Cell 2001, Thornborrow et al., Oncogene 2002, Hudson et al., J Biol Chem 2005, Sykes et al., Mol Cell 2006
  Evidence: mutant phenotype, reporter gene, physical interaction

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Bind Interaction: TP53 — SP1 Sawaya et al., J Biol Chem 1998*
• IRef Bind Interaction: TP53 — SP1 St Clair et al., Mol Cell 2004*
• IRef Bind Interaction: TP53 — SP1 Sengupta et al., Oncogene 2005*
• IRef Bind Interaction: TP53 — SP1 Ohlsson et al., Endocrinology 1998*
• IRef Bind Interaction: Complex of SP1-TP53 Sawaya et al., J Biol Chem 1998*
• IRef Bind_translation Interaction: TP53 — SP1 (coimmunoprecipitation) Sawaya et al., J Biol Chem 1998*
• IRef Bind_translation Interaction: TP53 — SP1 (coimmunoprecipitation) St Clair et al., Mol Cell 2004*
• IRef Bind_translation Interaction: TP53 — SP1 (coimmunoprecipitation) Sengupta et al., Oncogene 2005*
• IRef Bind_translation Interaction: TP53 — SP1 (coimmunoprecipitation) Ohlsson et al., Endocrinology 1998*
• IRef Biogrid Interaction: SP1 — TP53 (physical association, affinity chromatography technology) Sawaya et al., J Biol Chem 1998*
• IRef Biogrid Interaction: SP1 — TP53 (colocalization, imaging technique) St Clair et al., Mol Cell 2004*
• IRef Biogrid Interaction: SP1 — TP53 (physical association, affinity chromatography technology) Innocente et al., FEBS Lett 2005*
• IRef Biogrid Interaction: SP1 — TP53 (physical association, affinity chromatography technology) Ohlsson et al., Endocrinology 1998*
• IRef Biogrid Interaction: SP1 — TP53 (physical association, affinity chromatography technology) Borellini et al., J Biol Chem 1993*
• IRef Biogrid Interaction: SP1 — TP53 (physical association, affinity chromatography technology) Jin et al., J Biol Chem 2008
• IRef Biogrid Interaction: SP1 — TP53 (physical association, affinity chromatography technology) Dhar et al., J Biol Chem 2006*
• IRef Biogrid Interaction: SP1 — TP53 (physical association, affinity chromatography technology) Lagger et al., Mol Cell Biol 2003*
• IRef Biogrid Interaction: SP1 — TP53 (direct interaction, pull down) Lagger et al., Mol Cell Biol 2003*
• IRef Biogrid Interaction: SP1 — TP53 (physical association, affinity chromatography technology) Sengupta et al., Oncogene 2005*
• IRef Biogrid Interaction: SP1 — TP53 (physical association, affinity chromatography technology) Lin et al., Cancer Res 2010*
• IRef Biogrid Interaction: SP1 — TP53 (physical association, affinity chromatography technology) Kim et al., Cell Physiol Biochem 2011*
• MIPS CORUM p53-SP1 complex: p53-SP1 complex complex (SP1-TP53) Sengupta et al., Oncogene 2005*
• IRef Corum Interaction: TP53 — SP1 (association, anti bait coimmunoprecipitation) Sengupta et al., Oncogene 2005*
• IRef Dip Interaction: TP53 — SP1 (physical association, anti bait coimmunoprecipitation) Hwang et al., Proc Natl Acad Sci U S A 2011*
• IRef Hprd Interaction: TP53 — SP1 (in vitro) Abramovitch et al., Horm Metab Res 2003*, Innocente et al., FEBS Lett 2005*, Koutsodontis et al., Biochem J 2005, Ohlsson et al., Endocrinology 1998*
• IRef Hprd Interaction: TP53 — SP1 (in vivo) Abramovitch et al., Horm Metab Res 2003*, Innocente et al., FEBS Lett 2005*, Koutsodontis et al., Biochem J 2005, Ohlsson et al., Endocrinology 1998*
• IRef Intact Interaction: TP53 — SP1 (physical association, anti bait coimmunoprecipitation) Innocente et al., FEBS Lett 2005*
• IRef Ophid Interaction: TP53 — SP1 (aggregation, confirmational text mining) Ohlsson et al., Endocrinology 1998*
• IRef Ophid Interaction: TP53 — SP1 (aggregation, interologs mapping) Brown et al., Bioinformatics 2005

Text-mined interactions from Literome

Kanaya et al., Clin Cancer Res 2000 : These findings suggest that p53 repressed telomerase activity through down-regulation of hTERT transcription and that interaction of p53 with Sp1 or other transcription factors may be involved in this regulation
Lee et al., Oncogene 2000 (Carcinoma, Hepatocellular...) : Wild-type p53 inhibited binding of transcription factors Sp1 and TBP on the P4 promoter, while p53mt249 enhanced the formation of transcriptional complexes through enhanced DNA-protein ( Sp1 or TBP ) and protein-protein ( Sp1 and TBP ) interactions ... p53mt249 stimulates transcription factor Sp1 phosphorylation which might be a cause of increased transcription factor binding on the P4 promoter while wild-type p53 does not
Xu et al., Oncogene 2000 (Breast Neoplasms...) : Finally, wt p53 inhibited Sp1 binding to the hTERT proximal promoter by forming a p53-Sp1 complex
Amini et al., J Biol Chem 2004 : Expression of p53 further enhanced the level of Vpr-Sp1 mediated transcription activation of p21 through the sequence spanning -84 to -74 and increased the DNA binding activity of Sp1 in the presence of Vpr. Results from glutathione S-transferase pull-down assay showed the association of Vpr with p53 in extracts containing Sp1
Pietrzak et al., Biol Chem 2008 : As shown by electrophoretic mobility shift assays, Sp1 binding to the sites located in the -295 to +16 MCL-1 promoter fragment was decreased in the presence of p53
Bheda et al., Oncogene 2008 : Wild-type p53 suppressed Sp1- and YY1 mediated induction of the EGFR promoter ... We conclude that acute loss of p53 in normal HKc induces EGFR expression by a mechanism that involves YY1 and Sp1 and does not require p53 binding to the EGFR promoter
Króliczak et al., Acta biochimica Polonica 2008 (Neoplasms) : Sp1 and NFkappaB binding to the probes resembling their putative binding sites present in the S100A6 promoter was decreased in the presence of wild type p53
Lin et al., Cancer Res 2010 (Lung Neoplasms) : Low level of exogenous Sp1 enhanced the repressive activity of endogenous p53 on the DNMT1 promoter whereas high level of Sp1 upregulated DNMT1 gene expression level in A549 ( p53 wild-type ) cells
Fuchs-Young et al., Breast Cancer Res Treat 2011 (Cell Transformation, Neoplastic...) : Previous studies from our laboratory have shown that p53 regulates ER expression transcriptionally, by binding the ER promoter and forming a complex with CARM1, CBP, c-Jun, RNA polymerase II and Sp1
Hwang et al., Proc Natl Acad Sci U S A 2011 (Neoplasm Invasiveness) : Wild-type p53 negatively regulates MET expression by two mechanisms : ( i ) transactivation of MET targeting miR-34, and ( ii ) inhibition of SP1 binding to MET promoter
Dhar et al., Cancer Res 2011 (Carcinoma, Squamous Cell...) : Exposure to DMBA and TPA activated p53 and decreased MnSOD expression via p53 mediated suppression of Sp1 binding to the MnSOD promoter in normal appearing skin and benign papillomas
Gu et al., J Cell Physiol 2012 (Breast Neoplasms) : Oldenlandia diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERa/Sp1 mediated p53 activation
Chew et al., J Biol Chem 2012 : Sulforaphane induction of p21 ( Cip1 ) cyclin dependent kinase inhibitor expression requires p53 and Sp1 transcription factors and is p53 dependent
Gualberto et al., J Biol Chem 1995 : The presence of Sp1 increased p53 binding to its recognition sequence in the HIV-1 LTR, and experiments in Drosophila cells show that Sp1 is necessary for full transactivation by mutant p53
Bargonetti et al., Cell Mol Biol Incl Cyto Enzymol 1997 : p53 represses Sp1 DNA binding and HIV-LTR directed transcription
Ohlsson et al., Endocrinology 1998 (Osteosarcoma) : p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I induced tyrosine phosphorylation in an osteosarcoma cell line : interaction between p53 and Sp1